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INTRODUCTION
Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and a leading reason for drug withdrawal from the market (1, 2) . Unlike intrinsic DILI, which is predictable, reproducible and dose-dependent, idiosyncratic DILI is unpredictable, not strictly dose-dependent, and while rare it accounts for 10-15% of ALF cases in the US (3, 4) .
Acetaminophen is one of the most widely used pain relievers worldwide. While relatively safe, acetaminophen is a dose-dependent hepatotoxin that can cause intrinsic DILI. The use of acetaminophen at therapeutic doses for more than a few days has been shown to elevate serum transaminases in one-third of patients (5) . Acetaminopheninduced liver damage is characterized by haemorrhagic centrilobular necrosis and high plasma transaminase levels in both humans and animals, which can evolve in some cases to ALF (6) . Although acetaminophen is metabolized to its glucuronidated and sulphated non-toxic metabolites in the liver, acetaminophen overdose saturates these pathways and the excess acetaminophen is metabolized by CYP2E1 into the reactive metabolite N-acetyl-p-benzoquinoneimine (NAPQI), which is rapidly conjugated with GSH resulting in non-toxic mercapturic acid and cysteine conjugates that are excreted in the urine (7, 8) . When glutathione levels are limited, free unconjugated NAPQI reacts with sulfhydryl groups on cysteine and lysine residues, generating NAPQI-protein adducts (acetaminophen-protein adducts) in hepatocytes, particularly in mitochondria, leading to mitochondrial dysfunction and cell death (7) (8) (9) . SH3BP5 (Sab), a mitochondrial outer membrane protein, has been identified as a key player in acetaminophen-induced hepatotoxicity. Knockdown or liver specific knockout of SH3BP5 inhibited sustained JNK activation and protected against acetaminophen hepatotoxicity (10) . Moreover, there is extensive experimental evidence that JNK M A N U S C R I P T
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GASTRO-D-18-01544-R2 Torres et al., 6 6 activation and its translocation to mitochondria contributes to acetaminophen hepatotoxicity (11, 12) .
Valproic acid (VPA) is widely prescribed for epilepsy and used as an anticonvulsant, which is eliminated by biotransformation through multiple pathways, including glucuronidation, cytochrome P-450 metabolism and mitochondrial β-oxidation (13) .
Besides inducing metabolic syndrome in overweight epileptic patients (14, 15) , longterm VPA therapy can cause hepatotoxicity that may progress to idiosyncratic ALF (13, 16) . VPA-mediated hepatotoxicity is characterized by necrosis, depletion of endogenous antioxidants and disruption of mitochondrial β-oxidation of fatty acids, which can contribute to hepatic steatosis (16) (17) (18) (19) (20) . Furthermore, VPA has been shown to inhibit HDAC and GSK3 signaling events (21, 22) and while reported to induce ER stress (23, 24), there are studies showing that VPA protects cells against ER stress-mediated apoptosis and atherosclerosis (25, 26).
As VPA has been shown to deplete glutathione levels and stimulate steroidogenesis by increasing mitochondrial cholesterol trafficking (27, 28), we hypothesized that VPA can sensitize to acetaminophen-mediated ALF independently of fasting by inducing STARD1, a mitochondrial protein that mediates the transport of cholesterol to the mitochondrial inner membrane (29), which results in impaired transport of glutathione into mitochondria (30, 31). Our data reveal that VPA pretreatment in non-fasted mice results in acetaminophen-induced ALF by a mechanism that requires the complimentary action of STARD1 and Sab-JNK1/2. 
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MATERIALS AND METHODS
Generation of mice with liver-specific STARD1 deletion.
All experimental protocols for animal use and handling met the guidelines of the Fig 1B, C) . Mice were backcrossed to C57BL/6J strain for nine generations. [8] [9] [10] week old STARD1 f/f littermates and STARD1 ∆Hep mice were treated with VPA, APAP and their combination as described below.
Mice with liver-specific deletion of Sab and JNK1+2.
Sab ∆Hep (C57BL/6N) and JNK1+2 ∆Hep (57BL/6J) mice were generated by treatment of Sab f/f mice or JNK1+2 f/f with AAV8.TBG.Cre as described previously (10) . JNK1+2 f/f mice were provided by Dr. Roger J. Davis, UMass Medical School, Worcester, MA.
FRGN mice with humanized liver and expansion of human hepatocytes.
Fah -/-/Rag2 -/-/Il2rg -/-/NOD (FRGN) mice were xenotransplantated with human adult hepatocytes (HH), as described before ( 
Results
Fasting or VPA pretreatment in non-fasted mice sensitizes to acetaminophen hepatotoxicity.
As fasting sensitizes to acetaminophen-mediated hepatotoxicity (37), we first examined whether fasting potentiated the hepatotoxicity of VPA+acetaminophen coadministration. While repeated VPA dosing to fasted mice did not cause hepatotoxicity, acetaminophen administration induced marked liver injury and centrilobular necrosis (Figure 1A and 1B) . However, the combination of VPA+acetaminophen did not further enhance the liver injury caused by acetaminophen alone, indicating that fasting sensitized to acetamionophen hepatotoxicity regardless of VPA pretreatment. In contrast, non-fasted mice were resistant to acetaminopheninduced liver injury when acetaminophen was given in the morning, in agreement with previous results (38) , and VPA administration (3 times/12 hours) did not cause liver damage (Figure 1C and 1D) . Intestingly, VPA pre-administration in non-fasted mice sensitized to acetaminophen-mediated hepatotoxicity similar to the injury seen in fasted mice following APAP administration ( Figure 1C and 1D) , with increased ALT release over time, which paralleled the liver injury seen by H&E (Figure 1E, F) . We next examined the survival of non-fasted mice to VPA pretreatment followed by the administration of a higher dose of acetaminophen (600mg/Kg). While non-fasted mice were resistant to VPA or acetaminophen alone, mice pretreated with VPA followed by acetaminophen administration died over time with a mortality rate of 40% by 8 days post acetaminophen administration that was similar to the rate observed in fasted mice after being given acetaminophen ( Figure 1G) . Moreover, treatment with
VPA+acetaminophen caused a higher rate of cell death in primary mouse hepatocytes (PMH) as revealed by Sytox Green staining compared to either drug alone ( Supplementary Figure 2A ).
Acetaminophen metabolism, glutathione homeostasis and mitochondrial function
following VPA+acetaminophen administration in non-fasted mice.
Unlike VPA or acetamionophen alone VPA+acetaminophen coadministration to nonfasted mice induced an early and time-dependent upregulation of CYP2E1 that paralleled the generation of NAPQI-protein adducts, similar to the levels induced by acetamionophen in fasted mice (Figure 2A) . Moreover, as glutathione is required for NAPQI detoxification, we next examined glutathione homeostasis in liver homogenate and mitochondrial fraction in non-fasted mice. As seen, total glutathione levels were moderately depleted 2 hours after VPA or acetaminophen alone, which increased by 4
hours post-treatment and recovered to control levels by 24 hours, while total glutathione levels remained significantly depleted at 4 hours after VPA+acetamionophen administration ( Figure 2B) , consistent with the kinetics of NAPQI-protein adduct formation. However, neither VPA nor acetaminophen alone affected mitochondrial glutathione levels, whereas the combination of VPA+acetaminophen markedly depleted mitochondrial glutathione stores as early as 2 hours post-treatment that remained significantly decreased by 4 hours (Figure 2B ). In line with the induction of CYP2E1 or NAPQI-adduct generation, acetamionophen administration to fasted mice depleted total and mitochondrial glutathione levels by 65-75%, similar to the depletion induced by VPA+acetaminophen administration in fed mice.
We next examined mitochondrial function using a metabolic flux analyzer to determine control ratio (State III/State IV) with respect to VPA or acetamionphen alone ( Figure   2C ), indicating impaired mitochondrial respiration.
VPA+acetaminophen upregulates STARD1 expression in non-fasted mice.
We next examined the homeostasis of cholesterol and its trafficking to mitochondria, which is known to regulate mitochondrial glutathione (30, 31). Interestingly, increased mitochondrial pool of cholesterol was an early event (4 hours) after giving VPA+acetaminophen ( Figure 2D) , even though free cholesterol levels increased afterwards as shown by the representative filipin staining at 24 hours (Figure 2E ), suggesting the activation of a specific mechanism that triggers the accumulation of free cholesterol in mitochondria. As STARD1 regulates mitochondrial cholesterol trafficking (29), we next examined its expression in response to drug administration. In contrast to VPA or acetaminophen alone, VPA+acetaminophen increased an early expression (4 hours) of STARD1 both at the mRNA and protein level (Figure 2F, G) .
To examine the pattern of STARD1 expression we performed immunohistochemical analysis in liver sections 24 hours after VPA+acetaminophen administration ( Figure   2H ), indicating predominant expression in the pericentral area, which is consistent with the characteristic haemorrhagic centrilobular necrosis seen in APAP hepatotoxicity.
These findings were accompanied by increased expression of phosphorylated STARD1
( Figure 2G) , which is known to increase its activity in the trafficking of cholesterol to mitochondria in steroidogenic cells (39, 40) . Moreover, the expression of hepatic VPA+acetaminophen induces ER stress and mitochondrial JNK activation in nonfasted mice.
As tunicamycin has been shown to induce the expression of STARD1 by triggering ER stress rather than SREBP2 activation (43) and consistent with the role of ER stress in the regulation of STAR family members (44, 45) , we next examined ER stress as a potential mechanism that regulate STARD1 expression. VPA+acetaminophen induced an early (2 hours) increase in the expression of several ER stress markers at the mRNA and protein levels (Figure 3 A, B) . The increase of ER stress markers was sustained at 4 hours post-treatment (Figure 3 C, D), suggesting the involvement of different arms of the ER stress pathway (e.g. IRE-1α and PERK). Moreover, immunohistochemical analyses revealed that VPA+acetaminophen increased CHOP expression in liver sections 24 hours post-treatment ( Figure 3E) , which exhibited predominant pericentral staining, similar to StARD1. Since ERK1/2 phosphorylates and regulates STARD1 activity (46), we next analyzed the expression of hepatic ERK1/2 in mice treated with
VPA+acetaminophen. As seen, the phospho-ERK/ERK increased 4 hours after VPA+acetaminophen compared to either drug alone ( Figure 3F ). In addition, we also examined whether VPA+acetaminophen enhanced the translocation of phosphorylated JNK to mitochondria, which has emerged as a crucial event for acute liver injury (10, 11) . As seen, increased translocation of phosphorylated JNK in mitochondria was observed 2 hours after VPA+acetaminophen, similar to the increase seen by acetaminophen treatment in fasted mice ( Figure 3G ).
Targeting ER stress prevents STARD1 upregulation and protects against
VPA+acetaminophen hepatotoxicity in non-fasted mice.
We examined the impact of interfering with ER stress on STARD1 expression and liver injury by VPA+acetaminophen administration. As seen, TUDCA abolished the
Torres et al., 14 14 induction of ER stress markers CHOP, sXBP1 and p-EIF2α 4 hours post-treatment with VPA+acetaminophen ( Figure 4A ). In line with these findings, TUDCA prevented the increased expression of CHOP in liver sections (24 hours) after VPA+acetaminophen ( Figure 4B) . Consistent with the induction of STARD1 by tunicamycin-induced ER stress (44) , TUDCA prevented the early (4 hours) STARD1 upregulation by VPA+acetaminophen (Figure 4 C, D ) and the sustained expression of STARD1 in liver sections as revealed by immunohistochemistry (24 hours) ( Figure 4E ) and its mitochondrial targeting examined by confocal imaging (Supplementary Figure 4) .
More importantly and in line with these events, TUDCA prevented the mitochondrial glutathione depletion induced by VPA+APAP ( Figure 4F ) and protected against liver injury caused by VPA+acetaminophen administration (Figure 4 
G, H).
Arylating quinones have been shown to induce ER stress (47) and correct protein folding in the ER requires appropriate redox environment. Thus, we addressed whether in addition to the role of NAPQI glutathione depletion can contribute to ER stress. PMH treated with diethylmaleate (DEM) severily depleted total glutathione content and increased the level of CHOP, indicating the onset of ER stress (Supplementary Figure   2B , C). In addition, DEM-induced CHOP upregulation was attenuated by glutathione replenishment with NAC (Supplementary Figure 2C) . Moreover, tunicamycin induced CHOP expression, as expected, that was ameliorated by NAC, suggesting a relationship between glutathione and ER stress regulation. Furthermore, in line with these in vitro findings, in vivo NAC administration to mice given VPA+acetaminophen restored total glutathione and mitochondrial glutathione stores ( Figure 5A ) and, importantly, atorvastatin prevented the increase in mitochondrial cholesterol levels and protected against VPA+acetaminophen-mediated liver injury (Supplementary Figure 7) .
We examined whether the protection of STARD1 ∆Hep mice was related to a lower translocation of phosphorylated JNK to mitochondria. As seen, the mitochondrial 
VPA sensitizes to acetaminophen hepatotoxicity in FRGN mice with humanized liver
To address the potential translational relevance of the preceding findings showing the sensitization of VPA to acetaminophen-mediated hepatotoxicity, we next explored the susceptibility of FRGN mice, a genetically engineered model that allows the repopulation of the murine liver with HH, to VPA+acetaminophen induced liver injury.
FRGN mice were repopulated with HH by more than 80% as revealed by the human albumin levels in serum and the expression of human fumaroylacetoacetate hydrolase (FAH) (Supplementary Figure 9A, B) . Non-fasted FRGN mice were treated with VPA followed by a single dose of acetaminophen and sacrified 24 after treatment. While nonfasted FGRN mice xenotransplanted with HH were resistant to VPA or acetaminophen their combination caused liver injury, as revealed by increased serum transaminases and H&E analyses (Supplementary Figure 9C, D) . In line with these findings, humanized FRGN mice given VPA+acetaminophen exhibited depletion of both total glutathione and mitochondrial glutathione levels (Supplementary Figure 10A) , as well as an increase in the expression of ER stress markers (Supplementary Figure 10B) , an an early increase in STARD1 mRNA levels (Supplementary Figure 10C) 
Discussion
Here, we uncover that while non-fasted mice are resistant to VPA or APAP administration, prior VPA dosing, at a concentration that yields therapeutic VPA levels, sensitizes to acetaminophen-mediated hepatotoxicity through the induction of an ER stress-mediated STARD1 upregulation, which promotes mitochondrial cholesterol loading and mitochondrial glutathione deletion.
Our data indicate that VPA+acetaminophen resulted in an early generation of NAPQIprotein adducts formation, a key event involved in acetaminophen-mediated hepatotoxicity, which paralleled the profound depletion of glutathione levels by VPA+acetaminophen in non-fasted mice. While treatment with VPA or acetaminophen alone in non-fasted mice was insufficient to accumulate NAPQI-protein adducts, both drugs caused an early and transient depletion of glutathione, which increased afterwards. These data suggest that in non-fasting conditions the generation of NAPQI from acetaminophen is metabolized at the expense of glutathione stores, implying the existence of a sufficient glutathione reservoir or unrestricted capacity for glutathione neosynthesis to conjugate NAPQI to prevent the NAPQI-protein adduct formation. In line with this scenario, we observed that VPA+acetaminophen administration induced the upregulation of CYP2E1 compared to either drug alone, suggesting that the metabolism of acetaminophen into NAPQI following VPA dosing occurs at a rate that may overwhelm the ability of glutathione to form non-toxic mercapturic conjugates.
Thus, the generation of NAPQI by the combination of VPA+acetaminophen but not by yielding covalent bonds with nucleophiles, such as cysteinyl thiols. The reported cytotoxicity of arylating quinones correlates with their ability to induce ER stress (47) .
As a partially substituted quinone, NAPQI´s affinity to form Michael adducts with protein thiols can account for the ability of VPA+acetaminophen to induce ER stress.
Although we did not examine the identity of the NAPQI-protein adducts not their intracellular site of generation following VPA+acetaminophen, it is conceivable that NAPQI may have formed Michael adducts with ER proteins to underlie the observed ER stress, as well as the covalent binding with intramitochondrial proteins, which are known to be a major target of acetaminophen metabolism (7, 8) . In addition to forming Michael protein adducts in the ER, the correct protein folding in the ER requires appropriate redox environment, matched by an appropriate glutathione homeostasis. As ER stress can be regulated by antioxidants and glutathione replenishment (49) , the ability of NAPQI to deplete glutathione levels may secondarily contribute to the onset of ER stress caused by VPA+acetaminophen treatment, in parallel with the outcome observed in PMH. In line with this scenario, we observe that NAC prevents the induction of ER stress by VPA+acetaminophen. In addition to the presence of its nucleophilic thiol, which could directly target NAPQI-protein adducts, NAC is a precursor of glutathione stimulating its synthesis by providing the rate-limiting cysteine precursor, and therefore it is conceivable that the protective effect of NAC in VPA+acetaminophen hepatotoxicity may imply a dual mechanism involving the prevention of NAQPI-protein adduct formation and glutathione replenishment, thereby 
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